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Abstract: Plasma cell dyscrasias, most commonly associated with paraproteinemia, are a 
diverse group of diseases. Monoclonal gammopathy of undeﬁ  ned signiﬁ  cance (MGUS) can 
precede multiple myeloma, a progressive neoplastic disease. MGUS occurs in association 
with a variety of other diseases and currently no treatment is recommended but rather “watch-
ful waiting”. Given that the size of the M-protein is a risk factor for disease progression, 
early intervention with the aim of reducing the paraprotein load would provide an innovative 
therapeutic tool. Preliminary results from our pilot study show a drop of between 5% and 30% 
serum paraprotein in patients taking curcumin compared with patients on placebo. Curcumin is 
a diferuloylmethane present in extracts of the rhizome of the Curcuma longa plant. As a natural 
product, this has exciting potential in the treatment of plasma cell dyscrasias.
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A paraprotein is a monoclonal immunoglobulin or immunoglobulin light chain (Bence 
Jones protein) present in blood or urine and arising from clonal proliferation of mature 
B cells, most commonly plasma cells or B-lymphocytes. Alternative terms include 
monoclonal protein or M-band.
Plasma cell dyscrasias, most commonly associated with paraproteinemia, are a 
diverse group of diseases which includes multiple myeloma, Waldenstrom’s macro-
globulinemia, heavy chain disease, monoclonal gammopathy of undeﬁ  ned signiﬁ  cance 
(MGUS), and immunocytic amyloidosis. The incidence of plasma cell dyscrasias is 
age-related, with 1% of persons over age 25 and 4% of those over age 70. Parapro-
teinemia is also associated with the non-Hodgkin lymphoma disorders CLL (chronic 
lymphocytic leukemia) and LPL (lymphoplasmacytic lymphoma).
MGUS or monoclonal gammopathy of undeﬁ  ned signiﬁ  cance, can precede multiple 
myeloma and is typiﬁ  ed by a serum M-protein value of 30 g/L, fewer than 10% 
plasma cells in the bone marrow, no or a small amount of M protein in the urine, and 
absence of lytic bone lesions, anemia, hypercalcemia or renal insufﬁ  ciency related 
to the plasma-cell proliferative process (Kyle and Rajkumar 2005). MGUS occurs in 
association with a variety of other diseases and currently no treatment is recommended; 
rather that patients should be observed for change in clinical and immunochemical 
status at 4–6 month intervals.
Overall the risk of progression of MGUS to myeloma or related disorder is 1% 
per year. Although the prevalence of MGUS increases with advancing age, after 
adjustment for the level of the M-protein, the annual risk of progression to myeloma 
or a related cancer is not affected by age or the duration of MGUS. Younger patients 
are more likely to have progression to cancer during their lifetime because they are at Biologics: Targets & Therapy 2008:2(1) 162
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risk for longer (Cook and Macdonald 2007). It is currently 
not possible to predict the course in any individual patient, 
and clinically symptomatic myeloma may not evolve for 
as long as 20 years. Myeloma is a progressive neoplastic 
disease and is often associated with multiple osteolytic 
lesions, hypercalcemia, anemia, renal damage, and increased 
susceptibility to bacterial infections. Myeloma is associated 
with a high mortality.
Parameters which are currently used to identify those 
patients at highest risk of developing disease progression 
Figure 1 Curcumin: Paraprotein levels (g/L).
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 Figure 2 Control: Paraprotein levels.
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are: the size of the M-protein, the type of M-protein with IgA 
and IgM paraproteins having a higher risk compared with 
IgG paraproteins, the percentage of bone marrow plasma 
cells, and an abnormal serum-free light chain ratio. Given 
the uncertainty of disease progression with MGUS, early 
intervention with the aim of reducing the paraprotein load 
would provide an innovative therapeutic tool.
Curcuma longa or turmeric is a tropical plant native to 
southern and southeastern tropical Asia. It is a perennial herb 
belonging to the ginger family. The most active component 
in turmeric is curcumin (Aggarwal et al 2005). Curcumin is 
a diferuloylmethane present in extracts of the rhizome of the 
Curcuma longa plant.
This non-nutritive phytochemical is pharmacologically 
safe, considering that it has been consumed as a dietary 
spice, at doses up to 100 mg/day, for centuries. Recent 
phase 1 clinical trials indicate that people can tolerate a 
dose as high as 8 g/day with no adverse effects (Sharma 
et al 2004).
A Medline search revealed over 1500 publications 
describing various activities of this polyphenol. Curcumin 
has been shown to suppress proliferation of a wide variety of 
tumor cells; to down-regulate transcription factors NF-KB, 
AP-1, and early growth response gene-1; to suppress the 
expression of cyclooxygenase-2, lipoxygenase, NO synthase, 
matrix metalloproteinase-9, urokinase-type plasminogen 
activator, tumor necrosis factor, chemokines, cell surface 
adhesion molecules and cyclin D1; to inhibit the expression 
of growth factor receptors (such as epidermal growth factor 
receptor and human epidermal growth factor receptor 2); 
and to inhibit the activity of JNK, protein tyrosine kinases, 
and several other protein serine/threonine kinases. This 
polyphenol has antioxidant and anti-inﬂ  ammatory activity 
and has been found to suppress tumor initiation, promotion 
and metastasis. Numerous reports suggest that curcumin has 
chemopreventive and chemotherapeutic effects. Curcumin 
has been shown to inhibit the proliferation of a wide variety 
of tumor cells, including multiple myeloma cells through the 
down-regulation of interleukin-6.
Nine different studies of the safety and efficacy of 
curcumin in humans have been reported (see Aggarwal et al 
2005). Over the past several years, numerous studies have 
been funded by the National Institutes of Health to investi-
gate the role of curcumin and its derivatives in treatment of 
patients with cancer. Additionally, M.D. Anderson Cancer 
Center at the University of Texas is involved in pre-clinical 
and clinical research of the anti-cancer mechanism and appli-
cation of curcuminoids in conditions including lung, breast, 
multiple myeloma, pancreatic, myelodysplatic syndrome, 
colon, prostate, head, and neck cancers.
How curcumin produces its therapeutic effects is not 
fully understood. It has been suggested that the effects are in 
part through the antioxidant and anti-inﬂ  ammatory action of 
curcumin. It appears likely that curcumin mediates its effects 
through other mechanisms as well.
We are conducting a single blind randomized controlled 
pilot study on 25 patients with paraproteinemia. Entry 
criteria included patients deﬁ  ned as having MGUS ie, the 
presence of a serum paraprotein (greater than 8 g/L and 
less than 40 g/L) with the exclusion of multiple myeloma. 
These patients are being monitored for a 6 month period of 
curcumin or placebo therapy. Curcumin or placebo is being 
administered orally as a 2 grams twice daily regimen. After 
one week on curcumin, there has been a drop of between 5% 
and 30% serum paraprotein in some patients, compared to 
controls (see ﬁ  gures). After 3 months of curcumin therapy, 
these reduced levels have remained suppressed. These excit-
ing ﬁ  ndings have prompted a double-blind, randomized, 
controlled trial. The beneﬁ  ts of the fall in paraprotein is 
uncertain. How long these reduced levels will remain sup-
pressed and what the clinical beneﬁ  ts are, remain to be seen. 
As a natural product, it has exciting potential in the treatment 
of plasma cell dyscrasias.
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